2025 Q3 -tulosraportti
83 päivää sitten43 min
45,00 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
0
Myynti
Määrä
156
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 31.10.2025 | |
| 2025 Q2 -tulosraportti | 11.7.2025 | |
| 2025 Q1 -tulosraportti | 30.4.2025 | |
| 2024 Q4 -tulosraportti | 12.2.2025 | |
| 2024 Q3 -tulosraportti | 1.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·18 t sitten
·3 päivää sittenAKBM: Industrial strength and Texas shield against Trump turmoil? 🚀🛡️ While the stock market is characterized by tariff fear and geopolitical noise, I believe Aker BioMarine (AKBM) is in a unique position that the market may not have fully priced in yet. Here are my points for why I am optimistic about 2026: Strategic Texas position: With its own factory in Houston, AKBM produces krill oil locally in the USA. In a time with threats of tariffs on Norwegian exports, their American presence functions as an effective shield. "Made in USA" is the best insurance one can have in today's political climate. Ten quarters of growth: We are not talking about a pipe dream. The company delivered at the end of 2025 its tenth consecutive quarter of growth. An EBITDA increase of 50 % in Q3 2025 shows enormous operational power and ability to significantly lift margins when volume increases. Lysoveta – A gigantic wild card: AKBM holds the rights to Lysoveta, which recently won innovation awards for brain health. This is a biotech segment that can open entirely new markets (Alzheimer's/cognitive health) and provides an "upside option" beyond the usual operations. The Asia engine: Growth in Asia, especially in South Korea and India, makes the company less vulnerable to fluctuations in Western markets. This provides a geographical diversification that few other Norwegian companies can match. My conclusion: AKBM combines rock-solid industrial operations with biotech upside. When the dust settles after the USA/Greenland headlines, I believe the fundamental numbers will safely send us over the 100-mark. What do you think? Is the Houston factory the underestimated factor that separates AKBM from the rest of the "export crowd" tomorrow? 💰📈 Sources: Aker BioMarine Q1, Q2 and Q3 reports 2025 (EBITDA growth and segment development). The company's overview of production facilities (Houston Manufacturing Plant). News updates from Complementary Medicines Australia (Lysoveta Innovation Award). Stock exchange announcements via Oslo Børs/Euronext.·2 päivää sittenNice summary. Other triggers are positive studies with krill Omega3 against muscle wasting during weight loss (Ozempic & co). Algae-based omega3 is also another segment that could become big in the long run. Both of these, in combination with lysoveta and today's "running business", mean that the company has enormous opportunities for further, strong growth. Encourage everyone to look at the Q3 report where much of this is addressed. The case also appears relatively AI-disruption proof. These are physical products that must be taken from the sea, transported/refined and further out to the consumer (and into the body). As well as needing a lot of studies, approvals and licenses along the way. Not something a new AI service can turn upside down overnight. Knowing that the company is to be sold in the long term, the whole thing appears to be an extremely exciting case with further upside as I see it.
·16.1.Investtech had an analysis of AKBM 14 Jan
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
83 päivää sitten43 min
45,00 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·18 t sitten
- ·3 päivää sittenAKBM: Industrial strength and Texas shield against Trump turmoil? 🚀🛡️ While the stock market is characterized by tariff fear and geopolitical noise, I believe Aker BioMarine (AKBM) is in a unique position that the market may not have fully priced in yet. Here are my points for why I am optimistic about 2026: Strategic Texas position: With its own factory in Houston, AKBM produces krill oil locally in the USA. In a time with threats of tariffs on Norwegian exports, their American presence functions as an effective shield. "Made in USA" is the best insurance one can have in today's political climate. Ten quarters of growth: We are not talking about a pipe dream. The company delivered at the end of 2025 its tenth consecutive quarter of growth. An EBITDA increase of 50 % in Q3 2025 shows enormous operational power and ability to significantly lift margins when volume increases. Lysoveta – A gigantic wild card: AKBM holds the rights to Lysoveta, which recently won innovation awards for brain health. This is a biotech segment that can open entirely new markets (Alzheimer's/cognitive health) and provides an "upside option" beyond the usual operations. The Asia engine: Growth in Asia, especially in South Korea and India, makes the company less vulnerable to fluctuations in Western markets. This provides a geographical diversification that few other Norwegian companies can match. My conclusion: AKBM combines rock-solid industrial operations with biotech upside. When the dust settles after the USA/Greenland headlines, I believe the fundamental numbers will safely send us over the 100-mark. What do you think? Is the Houston factory the underestimated factor that separates AKBM from the rest of the "export crowd" tomorrow? 💰📈 Sources: Aker BioMarine Q1, Q2 and Q3 reports 2025 (EBITDA growth and segment development). The company's overview of production facilities (Houston Manufacturing Plant). News updates from Complementary Medicines Australia (Lysoveta Innovation Award). Stock exchange announcements via Oslo Børs/Euronext.·2 päivää sittenNice summary. Other triggers are positive studies with krill Omega3 against muscle wasting during weight loss (Ozempic & co). Algae-based omega3 is also another segment that could become big in the long run. Both of these, in combination with lysoveta and today's "running business", mean that the company has enormous opportunities for further, strong growth. Encourage everyone to look at the Q3 report where much of this is addressed. The case also appears relatively AI-disruption proof. These are physical products that must be taken from the sea, transported/refined and further out to the consumer (and into the body). As well as needing a lot of studies, approvals and licenses along the way. Not something a new AI service can turn upside down overnight. Knowing that the company is to be sold in the long term, the whole thing appears to be an extremely exciting case with further upside as I see it.
- ·16.1.Investtech had an analysis of AKBM 14 Jan
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
0
Myynti
Määrä
156
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 31.10.2025 | |
| 2025 Q2 -tulosraportti | 11.7.2025 | |
| 2025 Q1 -tulosraportti | 30.4.2025 | |
| 2024 Q4 -tulosraportti | 12.2.2025 | |
| 2024 Q3 -tulosraportti | 1.11.2024 |
2025 Q3 -tulosraportti
83 päivää sitten43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 31.10.2025 | |
| 2025 Q2 -tulosraportti | 11.7.2025 | |
| 2025 Q1 -tulosraportti | 30.4.2025 | |
| 2024 Q4 -tulosraportti | 12.2.2025 | |
| 2024 Q3 -tulosraportti | 1.11.2024 |
45,00 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·18 t sitten
- ·3 päivää sittenAKBM: Industrial strength and Texas shield against Trump turmoil? 🚀🛡️ While the stock market is characterized by tariff fear and geopolitical noise, I believe Aker BioMarine (AKBM) is in a unique position that the market may not have fully priced in yet. Here are my points for why I am optimistic about 2026: Strategic Texas position: With its own factory in Houston, AKBM produces krill oil locally in the USA. In a time with threats of tariffs on Norwegian exports, their American presence functions as an effective shield. "Made in USA" is the best insurance one can have in today's political climate. Ten quarters of growth: We are not talking about a pipe dream. The company delivered at the end of 2025 its tenth consecutive quarter of growth. An EBITDA increase of 50 % in Q3 2025 shows enormous operational power and ability to significantly lift margins when volume increases. Lysoveta – A gigantic wild card: AKBM holds the rights to Lysoveta, which recently won innovation awards for brain health. This is a biotech segment that can open entirely new markets (Alzheimer's/cognitive health) and provides an "upside option" beyond the usual operations. The Asia engine: Growth in Asia, especially in South Korea and India, makes the company less vulnerable to fluctuations in Western markets. This provides a geographical diversification that few other Norwegian companies can match. My conclusion: AKBM combines rock-solid industrial operations with biotech upside. When the dust settles after the USA/Greenland headlines, I believe the fundamental numbers will safely send us over the 100-mark. What do you think? Is the Houston factory the underestimated factor that separates AKBM from the rest of the "export crowd" tomorrow? 💰📈 Sources: Aker BioMarine Q1, Q2 and Q3 reports 2025 (EBITDA growth and segment development). The company's overview of production facilities (Houston Manufacturing Plant). News updates from Complementary Medicines Australia (Lysoveta Innovation Award). Stock exchange announcements via Oslo Børs/Euronext.·2 päivää sittenNice summary. Other triggers are positive studies with krill Omega3 against muscle wasting during weight loss (Ozempic & co). Algae-based omega3 is also another segment that could become big in the long run. Both of these, in combination with lysoveta and today's "running business", mean that the company has enormous opportunities for further, strong growth. Encourage everyone to look at the Q3 report where much of this is addressed. The case also appears relatively AI-disruption proof. These are physical products that must be taken from the sea, transported/refined and further out to the consumer (and into the body). As well as needing a lot of studies, approvals and licenses along the way. Not something a new AI service can turn upside down overnight. Knowing that the company is to be sold in the long term, the whole thing appears to be an extremely exciting case with further upside as I see it.
- ·16.1.Investtech had an analysis of AKBM 14 Jan
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
0
Myynti
Määrä
156
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt